Document is current

Article History

Received: 3 October 2024

Accepted: 7 January 2025

First Online: 23 January 2025

Declaration

:

: Hiroyasu Kaneda reports financial support and equipment, drugs, or supplies were provided by Elli Lilly. Hiroyasu Kaneda reports a relationship with AstraZeneca that includes: speaking and lecture fees. Hiroyasu Kaneda reports a relationship with Chugai Pharmaceutical that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Haruko Daga reports a relationship with Astrazeneca that includes: speaking and lecture fees. Haruko Daga reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Kazuko Sakai reports a relationship with Life Technologies Japan Ltd. that includes: speaking and lecture fees. Kazuko Sakai reports a relationship with Takeda Pharmaceutical Co., Ltd. that includes: speaking and lecture fees. Kazuko Sakai reports a relationship with Qiagen, Inc. that includes: speaking and lecture fees. Kazuko Sakai reports a relationship with Nippon Kayaku Co.,Ltd. that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Kenji Sawa reports a relationship with Taiho Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with AstraZeneca that includes: speaking and lecture fees. Kenji Sawa reports a relationship with MSD KK that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Ono Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Nippon Kayaku Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Kyowa Kirin Co Ltd that includes: speaking and lecture fees. Kenji Sawa reports a relationship with Eli Lilly Japan KK that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Kazuto Nishio reports a relationship with Nichirei Biosciences Inc that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with West Japan Oncology Group that includes: funding grants. Kazuto Nishio reports a relationship with Eli Lilly Japan KK that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with Hitachi Ltd that includes: funding grants. Kazuto Nishio reports a relationship with Nippon Boehringer Ingelheim Co Ltd that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with Sysmex Corp that includes: funding grants. Kazuto Nishio reports a relationship with Otsuka pharmaceutical that includes: funding grants and speaking and lecture fees. Kazuto Nishio reports a relationship with Thoracic Oncology Research Group that includes: funding grants. Kazuto Nishio reports a relationship with University Public Corporation Osaka that includes: funding grants. Kazuto Nishio reports a relationship with Chugai Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with AstraZeneca that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Amgen Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Yakult Honsha Co Ltd that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Guardant Health Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with SymBio Pharmaceuticals Limited that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Takeda Pharmaceutical Company Limited that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Novartis Pharmaceuticals Corporation that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Pfizer Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with FUJIREBIO that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Bristol-Myers Squibb that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Merck Biopharma Deutschland that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with MSD that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Daiichi Sankyo Inc that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Ono Pharmaceutical Co Ltd that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Invitae Japan that includes: speaking and lecture fees. Kazuto Nishio reports a relationship with Maruho Co Ltd that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Tomoya Kawaguchi reports non-financial support from Eli Lilly co., during the conduct of the study; grants and personal fees from Chugai Pharma, grants and personal fees from Eli Lilly, personal fees from Astra Zeneca, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Bristol-Myers Squibb Japan, personal fees from MSD Oncology, personal fees from Pfizer, personal fees from Novartis, grants from Daiichi Sankyo, personal fees from Astellas Pharma, outside the submitted work.The remaining authors have no relevant financial or non-financial interests to disclose.